Delcath Systems, Inc. (DCTH)

NASDAQ: DCTH · Real-Time Price · USD
11.60
+0.04 (0.39%)
Apr 17, 2025, 4:00 PM EDT - Market closed
0.39%
Market Cap 388.48M
Revenue (ttm) 37.21M
Net Income (ttm) -26.39M
Shares Out 33.40M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 315,099
Open 11.40
Previous Close 11.55
Day's Range 11.40 - 11.83
52-Week Range 4.26 - 16.97
Beta 0.85
Analysts Strong Buy
Price Target 22.75 (+96.21%)
Earnings Date May 13, 2025

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1988
Employees 96
Stock Exchange NASDAQ
Ticker Symbol DCTH
Full Company Profile

Financial Performance

In 2024, Delcath Systems's revenue was $37.21 million, an increase of 1701.69% compared to the previous year's $2.07 million. Losses were -$26.39 million, -44.66% less than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $22.75, which is an increase of 96.21% from the latest price.

Price Target
$22.75
(96.21% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the public...

9 days ago - Business Wire

Hospitals Experience FOMO In Adopting Delcath's PHP Treatment

Delcath Systemsbeat Q4 sales estimates. This was driven by increased adoption of HEPZATO KIT. However, the stock fell due to the Biotech/Medtech bear market. Delcath reported its first profitable quar...

16 days ago - Seeking Alpha

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

25 days ago - Business Wire

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

5 weeks ago - Business Wire

Delcath Systems, Inc. (DCTH) Q4 2024 Earnings Call Transcript

Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gera...

6 weeks ago - Seeking Alpha

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

6 weeks ago - Business Wire

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...

2 months ago - Business Wire

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

2 months ago - Business Wire

Biotech walks a 'tightrope' amid unclear funding, regulations

Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se...

Other symbols: ELVNIBB
2 months ago - Yahoo Finance

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

2 months ago - Business Wire

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

3 months ago - Business Wire

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

3 months ago - Business Wire

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

3 months ago - Business Wire

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U...

4 months ago - Business Wire

Delcath Begins Platform Expansion With Two Phase 2 Trials

Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing...

5 months ago - Seeking Alpha

Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth

Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 act...

5 months ago - Seeking Alpha

Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript

Delcath Systems Inc (NASDAQ:DCTH) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Ger...

5 months ago - Seeking Alpha

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

5 months ago - Business Wire

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

6 months ago - Business Wire

Delcath Systems to Host Third Quarter 2024 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it ...

6 months ago - Business Wire

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

6 months ago - Business Wire

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

7 months ago - Business Wire

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup...

7 months ago - Business Wire

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver...

8 months ago - Business Wire

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...

8 months ago - Business Wire